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general practice. The mortality rate ratio was calculated and prevalence of depres-
sion compared. Additionally descriptive, non-comparative analysis of key clinical 
manifestations was presented. Results: We identified 605 subjects with CAH (41% 
male). Mean age at presentation was 11.0 (sd 19.9) years for males, 13.6 (sd 17.4) for 
females. 58% of subjects were diagnosed ≤ 6 years old. 562 patients with CAH (93%) 
could each be matched with 10 controls. The crude rate ratio for all-cause mortality 
in CAH vs. controls was 2.6 (95%CI 1.7–3.9). Lifetime prevalence of depression in CAH 
was 33% vs. 26% in controls (p< 0.001). In females the following morbidities were 
reported: adrenal crisis, hyponatraemia, 39 (11%); genital anomalies/surgery, 129 
(36%); precocious puberty, 34 (10%); hirsutism, virilism, 65 (18%); polycystic ovarian 
syndrome, 36 (10%); oligo/amenorrhoea, 42 (12%); infertility, 37 (10%). In males the 
following were reported: adrenal crisis, hyponatraemia, 30 (12%); precocious puberty, 
20 (8%); infertility, 12 (5%). ConClusions: Patients with CAH had significantly 
reduced survival and increased prevalence of depression compared with matched 
controls. Novel approaches to treating CAH that can alleviate the impact of this 
condition are required urgently.
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objeCtives: Autism, a heterogeneous disease, is described as a genetic psychiatry 
disorder. Multiple lines of evidence support the notion that most cases of autism 
likely have an underlying genetic cause or predisposition. Since folate and methyla-
tion (single carbon metabolism) are vital in neurological development, we routinely 
screened children for the common mutations of the methylenetetrahydrofolate 
reductase gene (MTHFR), which regulates this pathway. Common polymorphisms 
in the MTHFR gene have been associated with reduced enzyme activity. The study 
aims to analyze the chromosome alterations and rare mutations in MTHFR and its 
association in Autism patients. Methods: In the present study, in order to inves-
tigate the possible cytogenetic damage using peripheral blood lymphocyte culture 
(PBLC), and rare mutations of MTHFRthat have been reported to be associated with 
autism patients using PCR – SSCP method, and was carried out in the 25 autistic 
patient samples, based on the detailed DSM - IV questionnaire, and equal number 
of controls were selected. Results: In our study chromosomal alterations were 
frequently observed in chromosomes 2, 3, 7, 22 and X (2q32, 3q25-q27). In the present 
study, chromosomal aberrations showed higher degree in experimentals compared 
to controls (P< 0.001). We analysed the association between three single nucleotide 
polymorphisms (SNPs) of the MTHFR gene. No significant evidence between any 
SNPs of MTHFRgene in autism was observed. ConClusions: In conclusion, in 
this pilot study, we observed that the identification of cytogenetic abnormalities is 
not only important for providing a cause for the autism in a single individual but 
is also critical for accurate counselling regarding recurrence risks to parents and 
family members. We suggest that MTHFRmight represent a major susceptibility 
gene for autism.
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objeCtives: Rett syndrome (RTT) is a neurodevelopmental disorder that affects 
girls almost exclusively. This study aims to identify the genetic alterations of RTT 
by using the conventional cytogenetic techniques Trypsin G- banding with Mecp2 
genotype, and to estimate the role of association in Dopamine and serotonin lev-
els as a consequence of neurotransmitters. Methods: A total of 13 RTT patients 
were evaluated based on the Diagnostic and statistical manual of the American 
psychiatric association (DSM-IV). Human Peripheral blood Leukocyte culture for 
chromosomal analysis was screened, the genotypic polymorphism was analysed 
using the PCR-RFLP methods and Plasma GABA analysis and serotonin levels were 
also measured. Results: Abnormal karyotypes were found in the chromosomes 
17, 21, 22 and X. C to T transition in exon 2 of Mecp2 resulting in R106W amino 
acid substitution. 316 C to T transition nucleotide changes and R106W amino acid 
changes were observed in 7 subjects, 824delcins11 were seen in 4 subjects, 916 C 
to T nucleotide and R294W amino acid change in 2 patient each. Higher frequency 
of XCI was observed in subjects with severe RTT (Max. 95.5%). Among the neuro-
transmitter levels, elevated level of Dopamine and serotonin levels (p> -001) was 
measured. ConClusions: In conclusion, in this pilot study, we observed that the 
identification of cytogenetic abnormalities is not only important for providing a 
cause for the RTT in a single individual of twins and is also critical for accurate 
counseling regarding recurrence risks to parents and family members. Although 
these findings should interpret with caution, and larger, more standardized stud-
ies are warranted.Key Words: Rett syndrome, MECP2 mutation, neurotransmitters, 
chromosomal analysis
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objeCtives: To assess the effectiveness of CBL gene Mutation, which is a test per-
formed to check for mutations in the CBL (Casitas B-lineage Lymphoma) gene by 
sequencing in order to diagnose juvenile myelomonocytic leukemia (JMML) and 
determine the treatment strategy. Methods: We searched the 8 Korean databases 
within the Onabotulinum arm, and pain, constipation, dizzliness, and skin rush 
for triptans. ConClusions: Overall, Onabotulinum Toxin, a novel intravenous 
agent for the phrophylaxis treatment of Chronic Migraine, is well tolerated, and 
offer better tolerance and adherence in comparison with Oral Triptans.
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objeCtives: Once daily oral fingolimod (FTY720; Gilenya®, Novartis Pharma AG), 
is approved for the treatment of relapsing remitting multiple sclerosis(RRMS) in 
over 80 countries. As of February 2015, it is estimated that Gilenya® has been used 
to treat approximately 119,000 patients. The total patient exposure is approxi-
mately 218,500 patient years. PANGAEA (Post-Authorization Non-interventional 
German sAfety study of GilEnyA in RRMS patients) is a non-interventional study, 
conducted in Germany, to investigate long-term safety, tolerability and effective-
ness of fingolimod in daily clinical practice. Here we present data of the 36 months 
interim-analysis. Methods: Recruitment into PANGAEA finished in December 
2013. 4229 patients were enrolled. In this interim-analysis we present data from 
patients that are treated with fingolimod for up to 36 months. Results: The 
proportion of female patients was 71.6% and the mean age was 39.4 ±10.0 years. 
The annualized relapse rate of all PANGAEA patients improved from 1.5 (baseline) 
to 0.43 (month 12), 0.41 (month 24) and 0.37 (month 36). Of all enrolled PANGAEA 
patients 67.9% in the first, 68.3% in the second and 70.1% in the third year were 
relapse free. The mean EDSS of all PANGAEA patients was stable over 36 months 
at 3.0. In year 3 of PANGAEA 70.5% of the patients had no clinical disease activity 
measured by relapses and sustained EDSS progression. 10.8% of the patients dis-
continued the Fingolimod therapy in the first year (9.1% second year), 4,3% (2.3% 
second year) because of adverse events. 45.4% of the patients experienced no 
adverse events. Patients treatment satisfaction measured by the TSQM (Treatment 
Satisfaction Questionnaire for Medication)-9 Score, improved by 3 points over 
24 months. ConClusions: The results of the 36 months interim analysis of 
PANGAEA support the positive safety and effectiveness profile demonstrated in 
phase the III clinical trials. PANGAEA is a valuable source data for patients treated 
with fingolimod in daily clinical routine.
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objeCtives: Over the past 20 years, there have been research efforts, global ini-
tiatives, and new therapies aimed at awareness, diagnosis, and care of individuals 
with Alzheimer’s disease (AD). The OptumLabsTM Data Warehouse (OLDW), a large 
database including administrative claims data on privately insured and Medicare 
Advantage enrollees, was used to investigate 20-year trends in AD diagnoses and 
AD-specific drug prescribing. Methods: Demographics and prevalence of AD, as 
well as prescription counts for the treatment of AD were evaluated among individu-
als enrolled each year from 1996 to 2014. Prescription counts for the treatment of 
AD were identified as the number of individuals with at least one 30-day fill for 
a medication used to treat AD per year during the study period. New cases of AD 
were identified if they received a second AD diagnosis and/or were prescribed an 
AD-specific medication within six months of initial diagnosis. Additionally, individu-
als with major psychoses prior to AD diagnosis were excluded. Time trends were 
examined. Results: Prevalence of AD grew from 4 per 10,000 to 70 per 10,000 lives 
over time with the largest increase between 2005 and 2010. The majority of AD cases 
were female, Caucasian, and over 65 years of age at diagnosis. On average, 3,522 
new cases of AD were diagnosed annually. Donezipil has been the most commonly 
prescribed treatment for AD since its approval in 1997 followed by namenda, which 
was approved in 2003. In 2014, 51% and 30% of individuals with AD had at least 
one 30-day prescription for donezipil and namenda, respectively. ConClusions: 
Increased awareness, improved guidelines for diagnosis and more treatment options 
have contributed to a 23 fold-increase in AD diagnoses and subsequent increase in 
treatment over the last two decades.
PND4
the burDeN of IllNess of coNGeNItal aDreNal hyPerPlasIa IN the 
uNIteD kINGDom: a retrosPectIve, observatIoNal stuDy
Jenkins-Jones S1, Whitaker MJ2, Holden SE1, Morgan CL1, Ross RJ2, Currie CJ3
1Pharmatelligence, Cardiff, UK, 2University of Sheffield, Sheffield, UK, 3Cardiff University,  
Cardiff, UK
objeCtives: Congenital adrenal hyperplasia (CAH) comprises a group of disorders 
in which cortisol synthesis is disrupted. It may result in life-threatening adrenal 
crises and in symptoms such as genital ambiguity and hirsutism in females, preco-
cious puberty, and infertility, with associated effects on well-being. The purpose of 
this study was to evaluate all-cause mortality and depression and to characterise 
clinical manifestations of CAH in a UK primary-care population. Methods: Data 
were from the UK Clinical Practice Research Datalink (CPRD). Patients with a diag-
nosis of CAH and at least one prescription for a corticosteroid were selected, and 
matched 1:10 to a randomly drawn control group without CAH on gender, age and 
A750  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
1Cleveland Clinic, Cleveland, OH, USA, 2University of Alabama at Birmingham, Birmingham, AL, 
USA, 3Ruhr-University Bochum, Bochum, Germany, 4Biogen, Cambridge, MA, USA
objeCtives: Delayed-release dimethyl fumarate (DMF; also known as gastro-
resistant DMF) and fingolimod are oral disease-modifying treatments for relaps-
ing-remitting multiple sclerosis (RRMS). Direct comparisons of these agents are 
not possible due to a lack of head-to-head trials. In this study, comparative effec-
tiveness research was conducted by indirectly comparing efficacy outcomes at 2 
years with DMF or fingolimod treatment of RRMS in Phase 3 studies. Methods: 
Individual patient data from the DEFINE and CONFIRM studies of DMF (pooled) 
and aggregate data from the FREEDOMS and FREEDOMS II studies of fingolimod 
(pooled using random effects meta-analysis) were utilised. Only results using the 
approved dosage of DMF (240 mg twice daily) and fingolimod (0.5 mg once daily) 
are reported. Matching-adjusted indirect comparison was conducted as described 
in Signorovitch et al (2010). Patients in the pooled DMF trials were weighted such 
that their average baseline characteristics (age, gender, time from onset of symp-
toms, Expanded Disability Status Scale score, number of relapses in previous year) 
matched those reported for patients in pooled fingolimod trials. After matching, 
weighted efficacy outcomes for patients treated with DMF were compared with 
summary efficacy outcomes for patients treated with fingolimod. Results: After 
matching, all baseline characteristics were balanced between the pooled DMF tri-
als and the pooled fingolimod trials. At 2 years, annualised relapse rate ratio (95% 
confidence interval [CI]) for DMF vs placebo was 0.52 (0.43, 0.62) and for fingolimod 
vs placebo was 0.48 (0.42, 0.55). Twelve-week confirmed disease progression hazard 
ratio (95% CI) for DMF vs placebo was 0.70 (0.57, 0.85) and for fingolimod vs placebo 
was 0.76 (0.61, 0.95). Additional data, including comparison of DMF vs fingolimod, 
will be presented. ConClusions: In a matching-adjusted indirect comparison, the 
efficacy of DMF was similar to that of fingolimod on clinical measures of relapse 
and disability progression.
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objeCtives: Relapses and disability progression are the clinical hallmarks of MS 
and the two most commonly assessed endpoints for therapeutic interventions in 
clinical trials. For many patients relapses are the initial defining feature of MS. 
However, the accumulation of disability has the greatest long-term clinical, social 
and economic impact on patients and society. This study evaluated the compara-
tive efficacy of disease-modifying therapies for multiple sclerosis and ranked 
each therapy based on probabilities of being among the best treatments for each 
outcome. Methods: A network meta-analysis was conducted within a Bayesian 
framework to estimate comparative annualised relapse rates (ARR) and risks of 
disability progression (defined by both a 3-month, and 6-month confirmation 
interval). Cumulative ranking analysis, using the Surface Under the Cumulative 
RAnking curve (SUCRA) method, provided a ranking of treatments for each out-
come. Results: Alemtuzumab and natalizumab had the highest SUCRA scores 
for ARR (> 90%) and disability progression confirmed after three months (> 80%), 
while IFN β -1a 30mcg ranked lowest among active treatments for these outcomes. 
Ranking of treatments was affected by the definition of disability progression largely 
due to the conflicting results of IFN β -1b 250 mcg, ranking among the most effi-
cacious treatments for disability progression confirmed after six months (> 90%) 
and among the least efficacious for disability progression confirmed after three 
months (< 50%). Alemtuzumab and natalizumab both scored relatively highly for 
disability progression confirmed after six months. Notable variation in ranking 
across outcomes was observed for fingolimod (> 70% for ARR, < 50% for the disability 
progression outcomes). ConClusions: The magnitude of treatment effects and 
associated uncertainty varied between DMTs, and across outcomes. While natali-
zumab and alemtuzumab demonstrated consistently high ranking for both relapse 
and progression, with older interferon-beta and glatiramer acetate products ranking 
lowest, variation in disability progression definitions lead to variation in the relative 
ranking of treatments.
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objeCtives: Neuromyelitis Optica (NMO) has been described as a disease clinically 
characterised by severe optic neuritis and transverse myelitis. There are very few 
epidemiological studies in NMO and no randomised controlled studies that guide 
therapy. The aim of this review is to determine epidemiology of NMO and to provide 
an algorithm of treatment. Methods: A systematic search was conducted of the 
relevant published evidence from Embase, MEDLINE, and Cochrane. Search limits 
were articles in English and in human. Retrieved citations were screened by two 
independent reviewers according to inclusion criteria: NMO, incidence, prevalence, 
and treatments reported in population base and observational studies. The analy-
ses of comparable outcomes were carried out as per appropriate statistics along 
with critical appraisal of the studies. Results: A total 16 studies met the inclusion 
criteria including six studies reported epidemiological data while 10 other studies 
reported treatment algorithm. Incidence of NMO ranged from 0.05 per 100,000 per 
year in United Kingdom (UK) to 0.4 per 100,000 in Southern Denmark. Prevalence 
was ranged from 0.44 per 100,000 in UK to 4.4 per 100,000 in Southern Denmark. 
Peak prevalence of NMO occurs among the people at 40-49 years of age. Low level 
evidence recommended methylprednisolone 1g/day for 3 to 5 days or 2 to 3 ses-
sions of plasmapheresis per week, up to 7 sessions for acute attacks of NMO. Nine 
studies observed the improvements in the reduction of mean annualized relapse 
rate. ConClusions: There is limited evidence on current available treatment thera-
pies for NMO. The available low level evidence found that high dose intravenous 
and overseas databases including Ovid-MEDLINE, Ovid-EMBASE and Cochrane 
Library. Total of 274 studies were searched and 6 studies were included in the final 
assessment. Each of the stages from literature search and extraction of data were 
carried out independently by 2 researchers. Results: The effectiveness of CBL 
gene mutation test was assessed by CBL gene mutation detection rate, relevance 
between CBL gene mutation and clinical symptoms, and impact on medical deci-
sions. The CBL gene mutation detection rate was 5 to 19% among JMML patients. The 
hemoglobin level and age-at-diagnosis were both significantly low among patients 
with a CBL gene mutation (p= .02, p= .037). There was intent to assess the impact 
of detecting CBL gene mutation on the medical decisions such as changes in the 
treatment plan and/or method; however, there were no studies reporting on this 
matter. ConClusions: There is a need for quick and accurate diagnosis for JMML, 
which is an intractable disease occurring in childhood, and the test in question 
can be helpful in deciding on stem cell transplantation. Also, considering that CBL 
gene mutation occurs exclusively from other gene mutations (PTPN11, RAS, NF1, 
etc.) causing JMML, it was deemed that even a low detection rate of 5 to 19% had a 
clinical significance. The CBL gene mutation test is an effective test that can con-
tribute to the diagnosis of JMML and help determine the treatment strategy (Grade 
of recommendation: C).
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objeCtives: To compare confirmed disability improvement in propensity score 
(PS)-matched cohorts of patients receiving fingolimod or BRACE (beta-interferons 
or glatiramer acetate) following previous BRACE treatment, who had active multiple 
sclerosis (MS), using data from two German observational studies, PANGAEA and 
PEARL, respectively. Methods: Patients with active MS (≥ 1 relapse in the year 
before the study) from the PANGAEA and PEARL registries were included if they 
had received BRACE before participating in the studies and did not have miss-
ing relapse data in the previous year. Patients from the PANGAEA registry were 
excluded if they had participated in PEARL. Patients in the PANGAEA cohort 
were matched in a 3:1 ratio to patients in the PEARL cohort using a PS-matching 
approach. Time to 3-month and 6-month confirmed disability improvement was 
assessed using a Kaplan–Meier approach. Hazard ratios for confirmed disability 
improvement (fingolimod vs BRACE) were estimated using a Cox proportional haz-
ards model. Results: After PS matching, a total of 1535 patients were included 
(PANGAEA, n= 1163; PEARL, n= 372). The proportions of patients in the PANGAEA 
and PEARL cohorts with 3-month confirmed disability improvement were 14.6% and 
7.0%, respectively (p< 0.001). Similar results were seen for 6-month confirmed dis-
ability improvement (11.0% vs 6.2%; p< 0.001). The probability of 3-month confirmed 
disability improvement was significantly higher in PANGAEA compared with PEARL 
(175% increase; HR, 2.75; 95% CI, 1.82–4.15; p< 0.001). The corresponding value for 
6-month confirmed disability improvement was a 126% increase (2.26; 1.45–3.53; 
p< 0.001). Similar findings were found in subgroups of patients with at least 1 year of 
follow-up (3-month: 176% increase; 2.76, 1.80–4.22; p< 0.001; 6-month: 136% increase; 
2.36, 1.50–3.69; p< 0.001). ConClusions: This comparison of real-world cohorts 
of patients with MS demonstrates that fingolimod treatment is associated with 
statistically significant increases in the probability of confirmed disability improve-
ment compared with BRACE.
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objeCtives: BG-12 and Teriflunomide are the first two oral therapeutics for the 
treatment of Multiple Sclerosis. At the moment there is no direct comparison 
of these agents. The adjusted indirect comparison is a comparison of different 
therapies adjusted according to their direct comparison results against a common 
control, so that the strength of the randomised trials is preserved. Methods: A 
Systematic literature search was conducted in the databases of Medline, Embase 
and Cochrane. Due to a lack of direct evidence an adjusted indirect comparison 
by Bucher in efficacy endpoints was performed. The risk of bias tool was used to 
assess the methodological quality of the included studies. Results: 339 studies 
were identified in a systematic literature search. Finally four RCTs were eligible in 
which 4861 patients had been randomized. All included studies have a low risk of 
bias. There were no significant heterogeneity between the included studies in the 
operationalization of the relevant endpoints for AIC. Adjusted Indirect comparisons 
could be performed in the endpoints annual relapse rate, percentage of relapse 
free patients and percentage of patients with EDSS progression. In the annual-
ized relapse rate BG-12 gains a statistically significant 44% risk reduction against 
Laquinimod (RR= 0,66 [0,52;0,85]) and 26% against Teriflunomide (RR= 0,74 [0,56;0,99). 
In no other endpoint the results were significant. ConClusions: It can be assumed 
that the relapse risk under BG-12 is less than under Laquinimod or Teriflunomide. 
The possible superiority of BG-12 has to be checked with the help of further direct 
comparative RCTs.
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